Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From fossil to bio-circular plastics: the environmental benefits of bio-attributed acrylonitrile butadiene styrene in single-use cystoscopes.

BJU international·2026
Same author

Evidence Thresholds for Novel Therapeutic Strategies in Prostate Cancer: A Consensus Statement from the Prostate Cancer Committee of the French Urological Association.

The French journal of urology·2026
Same author

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy in the Era of Lesion-focused Sampling.

European urology focus·2026
Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes.

Urologic oncology·2026
Same author

Multicentre Validation of the 2019 Briganti Nomogram: One Threshold Does Not Fit All.

International braz j urol : official journal of the Brazilian Society of Urology·2026

Related Experiment Video

Updated: Jul 16, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer.

Arthur Peyrottes1, Michael Baboudjian2, Thibaut Long-Depaquit2,3

  • 1Department of Urology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.

JAMA Network Open
|July 15, 2026
PubMed
Summary

Magnetic resonance imaging (MRI) staging for prostate cancer shows similar accuracy to digital rectal examination (DRE) staging in predicting patient outcomes after radical prostatectomy. Integrating MRI staging into risk systems maintains prognostic performance without compromising accuracy.

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jul 16, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Area of Science:

  • Urology
  • Oncology
  • Radiology

Background:

  • Magnetic resonance imaging (MRI) is increasingly utilized for prostate cancer staging.
  • The comparative value of MRI versus digital rectal examination (DRE) for clinical T staging remains uncertain.

Purpose of the Study:

  • To compare the performance of MRI-based T staging against DRE-based T staging in men undergoing radical prostatectomy (RP).
  • To evaluate the impact of substituting MRI staging into established prognostic classification systems.

Main Methods:

  • A multicenter, retrospective case-control study involving 4425 men who underwent RP and preoperative multiparametric MRI.
  • MRI-derived T stage (iT) and DRE-derived T stage (cT) were incorporated into four established risk classification systems.
  • Outcomes assessed included distant metastasis-free survival, biochemical recurrence-free survival, and overall survival, analyzed using C-index and time-dependent AUC.

Main Results:

  • MRI-based staging demonstrated slightly higher discriminatory ability for biochemical recurrence-free survival (C-index, 0.62) and distant metastasis-free survival (0.67) compared to DRE staging (0.59 and 0.65, respectively).
  • However, MRI-based and DRE-based risk classification systems showed comparable discrimination with overlapping confidence intervals.
  • No significant differences in discrimination were observed during follow-up via time-dependent AUC analysis.

Conclusions:

  • MRI-based staging shows similar prognostic performance to DRE-based staging for predicting outcomes in prostate cancer patients undergoing RP.
  • MRI-derived staging can be integrated into current risk stratification systems without loss of accuracy.
  • These findings support the use of MRI in refining prostate cancer staging and risk assessment.